AKRO Quote, Financials, Valuation and Earnings

Allogene Therapeutics, Inc. has a net margin of -- compared to Akero Therapeutics, Inc.'s net margin of -295454.55%. Akero Therapeutics, Inc.'s return on equity of -32.14% beat Allogene Therapeutics, Inc.'s return on equity of -54.89%.

Akero Therapeutics, Inc. has a consensus price target of $56.00, signalling upside risk potential of 2.51%. On the other hand Allogene Therapeutics, Inc. has an analysts' consensus of $7.56 which suggests that it could grow by 425%. Given that Allogene Therapeutics, Inc. has higher upside potential than Akero Therapeutics, Inc., analysts believe Allogene Therapeutics, Inc. is more attractive than Akero Therapeutics, Inc..

Akero Therapeutics, Inc. has a beta of -0.399, which suggesting that the stock is 139.855% less volatile than S&P 500. In comparison Allogene Therapeutics, Inc. has a beta of 0.471, suggesting its less volatile than the S&P 500 by 52.924%.

Akero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allogene Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics, Inc. pays -- of its earnings as a dividend. Allogene Therapeutics, Inc. pays out -- of its earnings as a dividend.

Akero Therapeutics, Inc. quarterly revenues are --, which are smaller than Allogene Therapeutics, Inc. quarterly revenues of --. Akero Therapeutics, Inc.'s net income of -$81.6M is lower than Allogene Therapeutics, Inc.'s net income of -$41.4M. Notably, Akero Therapeutics, Inc.'s price-to-earnings ratio is -- while Allogene Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics, Inc. is -- versus 2,442.58x for Allogene Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bristol Myers Squibb Co. has a net margin of -- compared to Akero Therapeutics, Inc.'s net margin of 17.96%. Akero Therapeutics, Inc.'s return on equity of -32.14% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Akero Therapeutics, Inc. has a consensus price target of $56.00, signalling upside risk potential of 2.51%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $53.41 which suggests that it could grow by 2.81%. Given that Bristol Myers Squibb Co. has higher upside potential than Akero Therapeutics, Inc., analysts believe Bristol Myers Squibb Co. is more attractive than Akero Therapeutics, Inc..

Akero Therapeutics, Inc. has a beta of -0.399, which suggesting that the stock is 139.855% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.

Akero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.77% to investors and pays a quarterly dividend of $0.62 per share. Akero Therapeutics, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Akero Therapeutics, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Akero Therapeutics, Inc.'s net income of -$81.6M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Akero Therapeutics, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 17.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics, Inc. is -- versus 2.20x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Akero Therapeutics, Inc.'s net margin of 31.72%. Akero Therapeutics, Inc.'s return on equity of -32.14% beat Eli Lilly & Co.'s return on equity of 106.26%.

Akero Therapeutics, Inc. has a consensus price target of $56.00, signalling upside risk potential of 2.51%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.16%. Given that Eli Lilly & Co. has higher upside potential than Akero Therapeutics, Inc., analysts believe Eli Lilly & Co. is more attractive than Akero Therapeutics, Inc..

Akero Therapeutics, Inc. has a beta of -0.399, which suggesting that the stock is 139.855% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Akero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Akero Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Akero Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Akero Therapeutics, Inc.'s net income of -$81.6M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Akero Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics, Inc. is -- versus 15.57x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Akero Therapeutics, Inc.'s net margin of 21.32%. Akero Therapeutics, Inc.'s return on equity of -32.14% beat Pfizer Inc.'s return on equity of 10.84%.

Akero Therapeutics, Inc. has a consensus price target of $56.00, signalling upside risk potential of 2.51%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Pfizer Inc. has higher upside potential than Akero Therapeutics, Inc., analysts believe Pfizer Inc. is more attractive than Akero Therapeutics, Inc..

Akero Therapeutics, Inc. has a beta of -0.399, which suggesting that the stock is 139.855% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Akero Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Akero Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Akero Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Akero Therapeutics, Inc.'s net income of -$81.6M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Akero Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics, Inc. is -- versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.